Prospective evaluation of determinants of resistance to first-line therapy with an aromatase inhibitor (AI) and a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor in hormone receptor (HR) positive metastatic breast cancer (MBC)
Sibley Memorial Hospital
Johns Hopkins Kimmel Cancer Center in Baltimore
This research is being done to determine if we can predict which patients will respond to a combination of an aromatase inhibitor and palbociclib for metastatic breast cancer and which patients will not. We will use information from the tumor tissue and serial blood samples. We hope that a deeper understanding of which patients will respond to this combination and how resistance emerges will allow us to better tailor therapies for metastatic breast cancer.
Any man or woman 18 years or older being seen at Johns Hopkins for treatment of newly diagnosed estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) metastatic breast cancer may be join.
Participants enrolled in the study will have archived tissue or new biopsy collected at study enrollment. This tissue will undergo special molecular testing. If willing, we may also ask that subjects undergo a new biopsy if the disease worsens. Participants will also have blood collected at study enrollment and periodically thereafter. The blood samples will also undergo molecular testing, which is used to analyze biological markers in the genome, or an individual’s genetic code. Information from this testing will not be available to participants or their treating physicians as we do not know how this information should impact treatment.We will also collect information about which treatment participants receive and how their cancer responds.
03/05/2019 05:03 AM